News | 05 February 2024
TTK Healthcare posts Q3 FY24 PAT at Rs. 12.89 Cr
TTK Healthcare has reported total income of Rs. 199.75 crores during the period ended December 31, 2023
TTK Healthcare has reported total income of Rs. 199.75 crores during the period ended December 31, 2023
KIMS has reported total income of Rs. 609.091 crores during the period ended December 31, 2023
Delivers keynote address at the 4th convocation of AIIMS Jodhpur
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Thyrocare Technologies has reported total income of Rs. 137.47 crores during the period ended December 31, 2023
Dr. Lal Path Labs has reported total income of Rs. 557.2 crores during the period ended December 31, 2023
GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023
Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023
Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material
Combines biocompatibility, heat-resistance, transparency and durability
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Subscribe To Our Newsletter & Stay Updated
